DUBLIN–(BUSINESS WIRE)–The “3D Cell Culture Market by Type (Hydrogel, ECM, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation), Application (Cancer, Stem Cell, Toxicology, Tissue Engineering), End User (Pharma, Biotech, Research, Cosmetics), Region – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.
The global 3D cell culture market is valued at an estimated USD 1.3 billion in 2022 and is projected to reach USD 2.6 billion by 2027, at a CAGR of 15.6% during the forecast period.
The growth of this market is mainly driven by factors such as the increasing focus on developing alternative methods to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, a lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to restrain the growth of this market during the forecast period.
The scaffold-based 3D cell culture segment accounted for the highest growth rate in the 3D Cell culture market, by type, during the forecast period
In 2021, the scaffold-based 3D cell culture segment accounted for the highest growth rate. The advantages of scaffolds in 3D cell culture, such as structural rigidity, the availability of attachment points, and support, have greatly driven the preference for scaffold-based 3D cell cultures and ensured the large share of this segment.
Asia Pacific: The fastest-growing region in the 3D Cell culture market
The Asia Pacific market is estimated to record the highest CAGR during the forecast period. This is attributed to the presence of favorable regulatory guidelines, government support for cell culture-based vaccine production, low manufacturing costs, and the growing focus of global market players on emerging Asian countries.
Market Dynamics
Drivers
- Increasing Focus on Developing Alternatives to Animal Testing
- Growing Focus on Personalized Medicine
- Increasing Incidence of Chronic Diseases
- Availability of Funding for Research
- Growing Demand for 3D Cell Culture
Restraints
- Lack of Infrastructure for 3D Cell-Based Research
- High Cost of Cell Biology Research
Opportunities
- Emergence of Microfluidics-Based 3D Cell Culture
- Emerging Economies
- Regenerative Medicine as An Alternative to Organ Transplantation
- Risk of Pandemics and Communicable Diseases
Challenges
- Lack of Consistency in 3D Cell Culture Products
- Plastic Waste Disposal
Companies Mentioned
- Thermo Fisher Scientific (US)
- Merck KGaA (Germany)
- Corning Incorporated (US)
- Lonza Group AG (Switzerland)
- Avantor Inc. (US)
- Tecan Trading AG (Switzerland)
- 3D Biotek LLC (US)
- Emulate Inc. (US)
- CN Bio Innovations (UK)
- InSphero AG (Switzerland)
- Greiner Bio-One International GmbH (Austria)
- REPROCELL Inc. (Japan)
- Kirkstall Ltd (UK)
- MIMETAS BV (Netherlands)
- PromoCell GmbH (Germany)
- TissUse GmbH (Germany)
- Synthecon Incorporated (US)
- QGel SA (Switzerland)
- Lena Biosciences (US)
- Cellendes GmbH (Germany)
- Advanced BioMatrix Inc. (Part of BICO Group) (US)
- Visikol Inc. (US)
- SynVivo Inc. (US)
- UAB Ferentis (Lithuania)
- Hamilton Company(US)
For more information about this report visit https://www.researchandmarkets.com/r/b0hzxt
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900